Literature DB >> 8623759

Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma.

P L Nguyen1, L R Zukerberg, W F Benedict, N L Harris.   

Abstract

Mutations of p53 have been suggested to be involved in the histologic transformation of follicular lymphoma, but the role of the retinoblastoma (RB) gene, another tumor suppressor gene, in lymphomagenesis has not been established. To determine the roles of these tumor suppressor genes and their relationship with the anti-apoptotic bcl-2 gene in follicle center lymphoma, the immunohistochemical expression of p53, bcl-2, and RB proteins was correlated with cytologic grade in 50 cases of follicular lymphoma, and the results were compared to 23 cases of diffuse large B-cell lymphoma. The results showed that only 2 of 25 grade 1 follicular lymphoma were p53-positive compared to 16 of 25 grade 3 cases (P <.0001). A significantly lower number (13 of 25) of grade 3 follicular lymphomas expressed bcl-2 compared to grade 1 cases (23 of 25) (P <.004). Eight of 14 bcl-2-negative follicular lymphomas expressed p53, compared with 10 of 36 bcl-2-positive cases (P = .1). Twenty-four of 25 grade 3 follicular lymphomas showed 2+ to 3+ staining for RB protein compared to 9 of 21 grade 1 cases (P <.0002). Expression of p53 protein correlates significantly with higher cytologic grade in follicular lymphoma. Similar to earlier studies of breast cancer and lymphoma, there appears to be an inverse relationship between p53 and bcl-2 expression in follicular lymphoma. Inactivation of the retinoblastoma gene does not seem to be involved in the histogenesis of follicle center lymphoma or diffuse large B-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623759     DOI: 10.1093/ajcp/105.5.538

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Follicular lymphoma in Osaka, Japan: histological features and chronological change.

Authors:  Hajime Miyazato; Shin-ichi Nakatsuka; Itsuko Miyanaga; Hitoshi Hanamoto; Yoichi Tatsumi; Mitsuhiro Matsuda; Yasuhiro Maeda; Akihisa Kanamaru; Katsuyuki Aozasa
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.

Authors:  Tiemo Katzenberger; German Ott; Thomas Klein; Jörg Kalla; Hans Konrad Müller-Hermelink; M Michaela Ott
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

3.  Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

Authors:  W Y Chan; K K Cheung; J O Schorge; L W Huang; W R Welch; D A Bell; R S Berkowitz; S C Mok
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

4.  ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases.

Authors:  Olga K Weinberg; Weiyun Z Ai; M Rajan Mariappan; Carol Shum; Ronald Levy; Daniel A Arber
Journal:  J Mol Diagn       Date:  2007-07-25       Impact factor: 5.568

Review 5.  Cell kinetics and cell cycle regulation in lymphomas.

Authors:  L Leoncini; S Lazzi; C Bellan; P Tosi
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

6.  Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma.

Authors:  George Z Rassidakis; Raymond Lai; Marco Herling; Candy Cromwell; Annette Schmitt-Graeff; L Jeffrey Medeiros
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

7.  HPV Status and Its Correlation with BCL2, p21, p53, Rb, and Survivin Expression in Breast Cancer in a Chinese Population.

Authors:  Ya-Wen Wang; Kai Zhang; Song Zhao; Yanrong Lv; Jiang Zhu; Huantao Liu; Jinbo Feng; Weili Liang; Rong Ma; Jianli Wang
Journal:  Biomed Res Int       Date:  2017-12-20       Impact factor: 3.411

8.  Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer.

Authors:  R A Crawford; C Caldwell; R K Iles; D Lowe; J H Shepherd; T Chard
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.